Wellmont Holston Valley Hospital and Medical Center

Summary

Wellmont Holston Valley Hospital and Medical Center is a medical facility located in Kingsport, Tennessee. This center is recognized for care of Type 2 Diabetes, Breast Cancer, Breast cancer, Diabetes, Lung Cancer and other specialties. Wellmont Holston Valley Hospital and Medical Center is involved with conducting 121 clinical trials across 279 conditions. There are 4 research doctors associated with this hospital, such as Asheesh Shipstone, Joseph Ley, Morawski, and Emily Morawski, MD.

Top PIs

Clinical Trials running at Wellmont Holston Valley Hospital and Medical Center

Cancer

Lung Cancer

Bladder Cancer

Breast Cancer

Lymphoma

Breast cancer

Non-Small Cell Lung Cancer

Urothelial Carcinoma

Chronic Lymphocytic Leukemia

Ovarian Cancer

Olanzapine vs Megestrol Acetate

for Cancer-Related Anorexia

This trial tests whether olanzapine or megestrol acetate is better at increasing appetite in patients with advanced cancer. These patients often struggle with eating and weight loss. Both medications aim to make them feel hungrier, helping them eat more and gain weight. Megestrol acetate is known for its effectiveness in increasing appetite in patients with cancer.

Recruiting

2 awards

Phase 3

1 criteria

Sotorasib + Panitumumab

for Cancer

This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.

Recruiting

1 award

Phase 2

6 criteria

Neratinib or Neratinib + Palbociclib

for Cancer

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Recruiting

1 award

Phase 2